Literature DB >> 1361670

The effects of sandostatin and somatostatin on nociceptive transmission in the dorsal horn of the rat spinal cord.

V Chapman1, A H Dickenson.   

Abstract

The role of somatostatin and a stable analogue, sandostatin (Octreotide), on the responses of spinal cord neurones in vivo was investigated in the rat. Electrical C-fibre stimulation was used as a model of acute nociception and the response to subcutaneous formalin was used as a model of longer term events. Intrathecal pre-treatment with sandostatin and somatostatin did not alter the C-fibre response, wind up or A beta responses of the cells. However, intrathecal pre-treatment with sandostatin and somatostatin inhibited both the first and second phases of the formalin response dose dependently. Thus, sandostatin (20 micrograms) and somatostatin (150 micrograms) inhibited the first phase (66 +/- 12% inhibition and 52 +/- 13% respectively) and second phase (91 +/- 2% inhibition and 39 +/- 16% inhibition respectively). The second phase of the formalin response was more sensitive to somatostatin and sandostatin than the first. Sandostatin was approximately 400 times more potent than somatostatin on the second phase of the response. Subcutaneous sandostatin (100 mg/kg) significantly inhibited both the first and second phase of the formalin response whereas the local peripheral administration of sandostatin (20 micrograms) only inhibited the second phase of the formalin response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361670     DOI: 10.1016/0143-4179(92)90115-d

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  18 in total

1.  Tonic control of peripheral cutaneous nociceptors by somatostatin receptors.

Authors:  S M Carlton; J Du; S Zhou; R E Coggeshall
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

Review 2.  The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.

Authors:  D P Beltrutti; S Moessinger; G Varrassi
Journal:  Curr Rev Pain       Date:  2000

3.  Effects of octreotide on responses to colorectal distension in the rat.

Authors:  X Su; M B Burton; G F Gebhart
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

4.  Effects of Zusanli electroacupuncture on somatostatin expression in the rat brainstem.

Authors:  Qinghua Tian; Lihua Wang; Lifen Yao; Liming Zhang; Huixue Zhang
Journal:  J Mol Neurosci       Date:  2012-06-29       Impact factor: 3.444

5.  Colokinetic effect of somatostatin in the spinal defecation center in rats.

Authors:  Kiyotada Naitou; Takahiko Shiina; Hiroyuki Nakamori; Yuuki Sano; Hiroki Shimaoka; Yasutake Shimizu
Journal:  J Physiol Sci       Date:  2017-01-25       Impact factor: 2.781

6.  Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.

Authors:  Karen Wagner; Bora Inceoglu; Sarjeet S Gill; Bruce D Hammock
Journal:  J Agric Food Chem       Date:  2010-10-19       Impact factor: 5.279

7.  Effects of somatostatin on the responses of rostrally projecting spinal dorsal horn neurons to noxious stimuli in cats.

Authors:  Sung Jun Jung; Su-Hyun Jo; Sanghyuck Lee; Eunhui Oh; Min-Seok Kim; Woo Dong Nam; Seog Bae Oh
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

Review 8.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

Review 9.  Cluster headache, hypothalamus, and orexin.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2009-04

10.  Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro.

Authors:  Mark Connor; Elena E Bagley; Vanessa A Mitchell; Susan L Ingram; MacDonald J Christie; Patrick P A Humphrey; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.